Genedrive PLC Grant of options (7697D)
October 24 2022 - 2:00AM
UK Regulatory
TIDMGDR
RNS Number : 7697D
Genedrive PLC
24 October 2022
24 October 2022
genedrive plc
("genedrive" or the "Company")
Grant of Options
genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces that on 21 October 2022 share options
("Options") were granted to members of its senior management team
to acquire a total of 400,000 ordinary shares of 1.5p each
("Ordinary Shares") in the Company under the Company's Share Option
Scheme.
The Options have been granted with an exercise price of 12.25p
being equal to the closing price on the day before the grant and
vest after a period of three years, subject to certain performance
criteria being met through achieving revenue targets, achieving
cash targets and completing certain strategic projects in the year
ending 30 June 2025. The Options are exercisable over the period of
10 years from the date of grant.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. Sarah Barnett
2. Jonathan Barber
3. Gino Miele
4. Colleen Phythian
--------------------- --------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a. Position/status 1. Marketing Director
2. Operations Director
3. R&D Director
4. Director of Quality & Regulation
--------------------- --------------------------------------------------
a. Initial notification Initial notification
/Amendment
--------------------- --------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a. Name genedrive plc
--------------------- --------------------------------------------------
b. LEI 213800ZYODIRZ87Y4K14
--------------------- --------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a. Description Options over ordinary shares of 1.5 pence
of the each
Financial
instrument,
type
of instrument GB00B1VKB244
Identification
code
--------------------- --------------------------------------------------
b. Nature of Grant of options pursuant to and in accordance
the transaction with the terms of the Company's Share Option
Scheme dated 29 November 2017
--------------------- --------------------------------------------------
c. Price(s) and
volume(s)
PDMR Exercise No of Options
price
--------- --------------
Sarah Barnett 12.25p 100,000
--------- --------------
Jonathan
Barber 12.25p 100,000
--------- --------------
Gino Miele 12.25p 100,000
--------- --------------
Colleen
Phythian 12.25p 100,000
--------- --------------
--------------------- --------------------------------------------------
d. Aggregated
information N/A
Aggregated
volume
Price
--------------------- --------------------------------------------------
e. Date of the 21 October 2022
transaction
--------------------- --------------------------------------------------
f. Place of the Outside a trading venue
transaction
--------------------- --------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Duckworth
finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / George Dollemore / Nigel
Birks / Alice Lane
Walbrook PR Ltd (Media Relations +44 (0)20 7933 8780 or genedrive@walbrookpr.com
& Investor Relations)
Anna Dunphy +44 (0)7876 741 001
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMBBATMTTTBTT
(END) Dow Jones Newswires
October 24, 2022 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024
